secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2026-07-15T20:46:28+00:00
Accession:  0001193125-26-304880
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra receives FDA Type A meeting minutes for reproxalap NDA; plans Type D meeting by Q3 2026
--------------------------------------------------------------------------------

- Received minutes from Type A meeting with FDA on June 10, 2026 regarding reproxalap NDA for dry eye disease.
- Requested clarification of the minutes from FDA on July 15, 2026.
- Intends to request a Type D meeting to discuss potential resubmission of the NDA.
- Type D meeting expected to be held by the end of the third quarter of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/0001193125-26-304880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/aldx-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-304880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer